The $6.12M in open-market purchases by two 10% owners is a strong bullish signal. Monitor for any upcoming corporate catalyst (e.g., pipeline update, partnership, or earnings) that may have motivated the concentrated buying.
Price Chart
Executive Summary
Two 10% owners, including director Robert Nelsen and ARCH Venture Partners XII, LLC, each purchased 170,000 shares of City Therapeutics at $18.00 per share for a combined $6.12M in open-market buys. This cluster of large insider purchases by major shareholders signals strong conviction in the company's prospects, especially following a week of non-cash grants and derivative conversions by the CEO and other directors.
Key Financial Metrics
Key Facts
- Two 10% owners (Robert Nelsen and ARCH Venture Partners XII, LLC) each bought 170,000 shares at $18.00 on 2026-10-19.
- Total open-market purchase value: $6.12 million.
- All other insider activity in the prior week (grants, derivative conversions) was non-cash and not economically meaningful.
- The purchases represent a material insider buying by the most informed shareholders.
Financial Impact
Two 10% owners purchased $6.12M of stock at $18.00/share in open-market transactions.
Risk Factors
- No market cap data provided — proportionality relative to company size cannot be assessed, but $6.12M is a large absolute amount for most biotechs.
- Insider buying does not guarantee near-term stock appreciation; catalysts may take months to materialize.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CTY-1792472335190 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D | $20.79 | awaiting T+1 | — | $20.96 (+0.82%) |
Oct 26, 2026 today | SC 13G | $20.79 | awaiting T+1 | — | $20.96 (+0.82%) |
Oct 22, 2026 5d ago | SC 13G | $20.77 $20.77 | · 0.00% | ▲ +0.52% | $20.96 (+0.91%) |
Oct 19, 2026 7d ago | Insider Cluster | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $20.96 (+0.62%) |
Oct 19, 2026 7d ago | Press Release | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $20.96 (+0.62%) |
Oct 16, 2026 10d ago | 424B4 | $21.46 $20.83 | ▼ −2.94% | ▼ −3.27% | $20.96 (−2.33%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.96 (−6.43%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.96 (−6.43%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.96 (−6.43%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $20.96 (−6.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers